Series date: 
01/01/2023 - 11:00am to 12/31/2023 - 11:00am

DESCRIPTION
This is a monthly grand round series held the second Monday of the month at 12:00pm.

This is a multidisciplinary series designed to enhance collaboration between scientists, clinicians and fellows at all Mayo Clinic sites and learn from leaders and innovators in gastrointestinal (GI) and hepato-pancreatico-biliary (HPB) cancer treatment and research.  The group will focus on ground-breaking research, collaborative opportunities, and practice-related updates to ensure excellence in all aspects of GI and HPB cancers. 

TARGET AUDIENCE
The target audience includes physicians, scientist researcher PhD, nurse, nurse practitioner, pharmacist, and allied health professional.

LEARNING OBJECTIVES
Upon conclusion of this activity, participants should be able to:

  • Define GI and HPB Cancer Care delivery research and its importance for improving cancer care
  • Illustrate examples of successful GI and HPB cancer care delivery research conducted at Mayo Clinic
  • Identify practice-related changes in GI and HPB cancers and what intervention is needed to optimize change

Accreditation Statement
In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.



Credit Statement(s):
AMA
Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Summary
As a provider accredited by Joint Accreditation for Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science must ensure balance, independence, objectivity and scientific rigor in its educational activities.  All who are in a position to control the content are required to disclose all financial relationships with any ineligible company.   Faculty will also identify any off-label and/or investigational use of pharmaceuticals or instruments discussed in their content for FDA compliance.

Listed below are individuals with control of the content of this program who have disclosed...

Relevant financial relationship(s) with ineligible companies:
Tanios Bekaii-Saab, M.D.                
Consulting: Stemline, AbbVie, Boehringer Ingelheim, Janssen, Daiichi Sankyo, Natera, TreosBio, Celularity, Caladrius Biosciences, Exact Science, Sobi, Beigene, Kanaph, Astra.
Research Funding (to institution): Agios, Arys, Arcus, Atreca, Boston Biomedical, Bayer, Eisai, Celgene, Lilly, Ipsen, Clovis, Seattle Genetics, Genentech, Novartis

All relevant financial relationships have been mitigated. 

No relevant financial relationship(s) with ineligible companies:
Sean Cleary, M.D. 
Sara Hoheisel, M.S., M.H.A.
 
References to off-label usage(s) of pharmaceuticals or instruments in their presentation:
None

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s), please go here.

ATTENDANCE/CREDIT
Text the session code (provided only at the session) to 507-200-3010 within 48 hours of the live presentation to record attendance.  All learners are encouraged to text attendance regardless of credit needs.  This number is only used for receiving text messages related to tracking attendance.  Additional tasks to obtain credit may be required based on the specific activity requirements and will be announced accordingly. Swiping your badge will not provide credit; that process is only applicable to meet GME requirements for Residents & Fellows.

TRANSCRIPT
Any credit or attendance awarded from this series will appear on your Transcript.

COURSE DIRECTORS
Tanios Bekaii-Saab, M.D. (added 6/19/2023)

QUESTIONS?
Contact Sara Hoheisel, M.S., M.H.A
Support location: 
Minnesota

Sessions

Session Date
GI and HPB Cancer Grand Rounds 2023 : Beyond Boundaries: Next Generation Staging and Imaging Modalities to Improve Pancreatic Cancer Outcomes 09/18/2023 - 12:00pm to 1:00pm
GI and HPB Cancer Grand Rounds 2023: Using quantitative digital pathology to analyze features predictive recurrence in colorectal cancer, Early onset and hereditary gastrointestinal cancers clinic 10/09/2023 - 12:00pm to 1:00pm
GI and HPB Cancer Grand Rounds 2023: Evolving role of systemic therapy and personalized approaches in biliary cancers 11/13/2023 - 11:00am to 12:00pm
GI and HPB Cancer Grand Rounds 2023 : Lessons implementing CAR-T in GI cancers: Claudin18.2 as the first experience for Mayo Clinic 12/18/2023 - 12:00pm to 1:00pm